Skip to main content

Table 1 Patient and tumor characteristics

From: Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma

Specimen description Stage Age (years) TNM Nuclear grade ER PR p53 status HER2/neu
Initial sample
   43 DCIS (pure) 0 37 T3N0M0 ND - - + ND
   44 DCIS (pure) 0 44 ToN0M0 2 and 3 + + - +
   46 DCIS (pure) 0 43 T2N0M0 3 + + - + (3+)
   48 DCIS (pure) 0 52 T2N0M0 3 + + - + (3+)
   49 DCIS (pure) 0 58 TicN0M0 3 (High grade) - - - + (3+)
   2 DCIS IIa 48 T2N0M0 3 + + + +
   13 DCIS IIa 75 T2N0M0 2 + + + + (2+)
   25 DCIS IIa 34 T2N0M0 3 + + + + (3+)
   33 DCIS I 38 T1cN0M0 3 + - - -
   45 DCIS I 55 T1N0M0 3 - - + + (3+)
   66 DCIS IIIb 44 T4bN1M0 3 + + + - (1+)
   69 DCIS IIb/IIIa 57 T2N1M0/pT2N2M0 2 + + ND + (2+)
   75 DCIS IIb 43 pT2N0M0 IDC 2/DCIS 3 - - + + (3+)
   85 DCIS I 73 T1cN0M0 pT3N0M0 2 + + - + (2+)
   86 DCIS ND 46 T2N1M0 3 + + + + (2+)
   87 DCIS IIa 48 T2N1M0 3 - - - + (2+)
   1 IDC IIa 45 T2N0M0 2 - - - + (3+)
   3 IDC IIa 43 T1cN0M0 3 + - - + (3+)
   24 IDC IIa 54 T2N0M0 3 + + + + (3+)
   50 IDC III b 71 T4N2M0 3 + + + + (2+)
   51 IDC II a 43 initial T2N0M0 3 - ND ND + (3+)
   53 IDC III a 43 T2N2M0 3 + + ND + (2+)
   56 IDC I ND ND ND ND ND ND ND
   80 IDC IIa 44 pT1cpN1M0 3 + + - -
   81 IDC IIb 31 T2N1M0 3 - - + + (3+)
   83 IDC IIa 48 T2N0M0 2 + + - + (2+)
Independent group of DCIS/IDC samples
   1 DCIS ND 58 T1N0M0 3 + + + + (2+)
   2 DCIS ND 40 T1N1M0 3 + + - + (2+)
   3 DCIS ND 27 T1N0M0 1 (Low grade) ND ND ND ND
   4 DCIS ND 53 ND 3 (High grade) + + + + (2+)
   5 DCIS ND 51 T1N0M0 2 + + ND + (2+)
   6 DCIS III a 54 T3N1M0 3 (High grade) - - ND ND
   8 DCIS ND 52 T2N1M0 3 - - + + (3+)
   9 DCIS ND 38 T1N1M0 3 (High grade) - - + - (1+)
   3 DCIS ND 39 T2N0M0 ND + + + -
   8 DCIS ND 49 T2N0M0 ND + + ND -
   15 DCIS II b 69 T2N1M0 ND + + ND + (2+)
  1. Unless otherwise stated, 'DCIS' means in situ component of DCIS-IDC. DCIS, ductal carcinoma in situ; DCIS-IDC, ductal carcinoma in situ with co-existing invasive ductal carcinoma; ER, estrogen receptor; IDC, invasive ductal carcinoma; ND, not determined; PR, progesterone receptor; TNM, tumor size, nodal status and metastasis.